Home World News iDFS Benefit with Ribociclib Plus Nonsteroidal Aromatase Inhibitor in Patients with HR-positive,... World News iDFS Benefit with Ribociclib Plus Nonsteroidal Aromatase Inhibitor in Patients with HR-positive, HER2-negative Early Breast Cancer By Ogkologos - November 14, 2024 925 0 Facebook Twitter Google+ Pinterest WhatsApp Final invasive disease-free survival results from the NATALEE study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Simple Hysterectomy Noninferior to Radical Hysterectomy with Respect to Pelvic Recurrence... February 29, 2024 Reunión anual de la American Society of Clinical Oncology de 2022:... June 6, 2022 EMA Adopts a Positive Opinion for Biosimilar Denosumab May 28, 2025 Complete Cancer Prevalence in Europe in 2020 Reveals an Increased Proportion... February 1, 2024 Load more HOT NEWS Research with integrity – the importance of communication FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof... First-Line Treatment with Encorafenib Plus Cetuximab Plus mFOLFOX6 Significantly Improves ORR... ALK Mutations and Amplifications are Independent Predictors of Poorer Survival in...